AMRN
Amarin Corporation PLCNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Nov. 3, 9:47 AM
    • Amarin (AMRN +1.4%) Q3 results: Revenues: $32.7M (+52.1%); Operating Loss: ($15.3M) (+40.7%); Net Loss: ($15.8M) (+51.1%); Loss Per Share: ($0.08) (+55.6%); Quick Assets: $117.6M (+9.9%).
    • 2016 Guidance: Net Product Revenue: $112M - 125M.
    | Thu, Nov. 3, 9:47 AM | 8 Comments
  • Thu, Nov. 3, 5:32 AM
    • Amarin (NASDAQ:AMRN): Q3 EPS of -$0.08 beats by $0.02.
    • Revenue of $32.73M (+52.4% Y/Y) beats by $0.7M.
    • Press Release
    | Thu, Nov. 3, 5:32 AM
  • Wed, Nov. 2, 5:30 PM
  • Fri, Oct. 21, 7:40 AM
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $14 (272% upside) price target by H.C. Wainwright.
    • Catalent (NYSE:CTLT) initiated with Overweight rating and $29 (19% upside) price target by KeyBanc.
    • Coherus Biosciences (NASDAQ:CHRS) initiated with Outperform rating and $40 (32% upside) price target by Baird.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $5 (58% upside) price target by Citigroup.
    • AC Immune (Pending:ACIU) initiated with Outperform rating and $18 (20% upside) price target by Credit Suisse.
    • Sarepta Therapeutics (NASDAQ:SRPT) initiated with Outperform rating and $68 (39% upside) price target by Credit Suisse.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Buy rating and $62 (36% upside) price target by Needham.
    • AbbVie (NYSE:ABBV) initiated with Market Perform rating and $70 (13% upside) price target by Leerink Swann.
    • Stryker (NYSE:SYK) initiated with Buy rating and $140 (22% upside) price target by SunTrust Robinson Humphrey.
    | Fri, Oct. 21, 7:40 AM | 3 Comments
  • Wed, Oct. 19, 9:14 AM
    | Wed, Oct. 19, 9:14 AM
  • Fri, Oct. 7, 11:48 AM
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) initiated with Buy rating and $26 (38% upside) price target by H.C. Wainwright.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and $22 (54% upside) price target by H.C. Wainwright.
    • Mazor Robotics (NASDAQ:MZOR) initiated with Buy rating and $25 (10% upside) price target by B. Riley.
    • Lipocine (NASDAQ:LPCN) initiated with Buy rating and $25 (350% upside) price target by H.C. Wainwright.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating and $28 (218% upside) price target by Brean Capital.
    • Immunomedics (NASDAQ:IMMU) initiated with Buy rating and $5.50 (113% upside) price target by Jefferies.
    • AmerisourceBergen (NYSE:ABC) initiated with Neutral rating by UBS.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Buy rating and $22 (65% upside) price target by SunTrust Robinson Humphrey.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $6 (92% upside) price target by Cantor Fitzgerald.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) initiated with Buy rating and $17 (94% upside) price target by Cantor Fitzgerald.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (142% upside) price target by Brean Capital.
    • Zogenix (NASDAQ:ZGNX) initiated with Outperform rating and $17 (64% upside) price target by Leerink Swann.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $162 (23% upside) price target by Leerink Swann. Initiated with Buy rating and $189 (44% upside) price target by Goldman Sachs.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Outperform rating and $68 (57% upside) price target by Leerink Swann.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $221 (79% upside) price target by Brean Capital.
    • Axsome Therapeutics (NASDAQ:AXSM) initiated with Buy rating and $20 (136% upside) price target by Brean Capital.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (156% upside) price target by Brean Capital.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $16 (226% upside) price target by Brean Capital.
    • Sorrento Therapeutics (NASDAQ:SRNE) initiated with Buy rating and $15 (94% upside) price target by Roth Capital.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Outperform rating and a $75 - 81 (322% upside from midpoint) target price range by Wells Fargo.
    • Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Buy rating and $45 (49% upside) price target by Brean Capital.
    | Fri, Oct. 7, 11:48 AM | 8 Comments
  • Mon, Sep. 12, 11:00 AM
    | Mon, Sep. 12, 11:00 AM
  • Mon, Sep. 12, 9:15 AM
    | Mon, Sep. 12, 9:15 AM
  • Mon, Sep. 12, 7:10 AM
    • Amarin (NASDAQ:AMRN) eases 6% premarket on average volume in response to its announcement that its cardiovascular (CV) outcomes study, REDUCE-IT, evaluating whether Vascepa (icosapent ethyl) reduces CV events in patients with elevated triglyceride levels and other CV risk factors despite being on stabilized statin therapy, will continue as planned. The decision was based on the recommendation of the independent Data Monitoring Committee after its review of the first pre-specified interim efficacy analysis.
    • Per the study protocol, the first interim analysis was performed after 60% of the target 1,612 aggregate primary CV events occurred in the 8,175-subject study. The second interim analysis will be done when 80% of the target aggregate CV events have occurred, projected to happen in mid-2017. The database will be locked and the study stopped at this point or at the final analysis, projected to be at the end of 2017.
    • Vascepa (AMR101) consists of one gram of the omega-3 acid know as EPA in ethyl-ester form. The company says it is not fish oil, but derived from fish. It is currently approved in the U.S. as an adjunct to diet to reduce triglyceride levels in adults with hypertriglyceridemia (>= 500 mb/dL).
    • Shares have quadrupled since bottoming at $0.78 on November 11, 2014.
    | Mon, Sep. 12, 7:10 AM | 3 Comments
  • Thu, Aug. 11, 11:00 AM
    | Thu, Aug. 11, 11:00 AM | 3 Comments
  • Thu, Aug. 11, 10:28 AM
    • Amarin (AMRN -9.6%) prices its public offering of 21M ADSs at $2.85. Closing date is August 16.
    • Yesterday's close was $3.32.
    | Thu, Aug. 11, 10:28 AM | 1 Comment
  • Thu, Aug. 11, 9:15 AM
    | Thu, Aug. 11, 9:15 AM | 5 Comments
  • Wed, Aug. 10, 5:35 PM
    | Wed, Aug. 10, 5:35 PM
  • Wed, Aug. 10, 5:30 PM
    • Amarin (NASDAQ:AMRN) is down 10% after hours on robust volume in response to its announcement that it has initiated a public offering of American Depositary Shares pursuant to a shelf registration. Price, volume and terms have yet to be released.
    • Update: The company priced its offering of 21M ADSs at $2.85. Closing date is August 16.
    | Wed, Aug. 10, 5:30 PM | 6 Comments
  • Thu, Aug. 4, 10:21 AM
    • Amarin (AMRN -7.2%) Q2 results: Revenues: $33.1M (+87.0%); R&D Expense: $12.6M (+5.0%); SG&A: $26.1M; Operating Loss: ($14.4M) (+46.1%); Net Loss: ($13.4M) (+78.7%); Loss Per Share : ($0.07) (+80.0%); Non-GAAP Loss Per Share: ($0.09) (+40.0%); Quick Assets: $72.5M (-32.2%).
    • 2016 Guidance: Net Product Revenue: $112M - 125M.
    | Thu, Aug. 4, 10:21 AM | 8 Comments
  • Thu, Aug. 4, 9:16 AM
    | Thu, Aug. 4, 9:16 AM | 2 Comments